Apollo Hospitals Enterprise Limited (APOLLOHOSP) AI Stock Analysis

• Market Cap: ₹1.14T
• Dividend Yield: 0.24%
• Average Volume (3M): 4.82K
• Price to Earnings (P/E): 72.3
• Beta (1Y): 1.02
• Revenue Growth: 14.31%
• EPS Growth: 51.71%
• Country: IN
• Employees: 83,147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 30.10
• Shares Outstanding: 143,784,650
• 10 Day Avg. Volume: 6,428
• 30 Day Avg. Volume: 4,819
• PEG Ratio: 1.08
• Price to Book (P/B): 11.61
• Price to Sales (P/S): 4.38
• P/FCF Ratio: 441.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹8,781.25
• Price Target Upside: 11.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 64 Neutral
• Price Target: ₹8,201.00 ▲(4.03% Upside)

Apollo Hospitals' strong financial performance is the primary driver of its stock score, supported by stable revenue growth and profitability. However, the high P/E ratio and mixed technical indicators suggest caution, as the stock may face short-term volatility and valuation concerns.

Apollo Hospitals Enterprise Limited Business Overview & Revenue Model

Company Description

Apollo Hospitals Enterprise Limited (APOLLOHOSP) is one of India's leading healthcare providers, known for its extensive network of hospitals, clinics, and pharmacies. Established in 1983, the company operates in various sectors of healthcare, including tertiary and quaternary care hospitals, diagnostic services, and retail pharmacies. Apollo Hospitals is renowned for its advanced medical technology, comprehensive patient care, and a wide range of healthcare services, including outpatient services, health insurance, and wellness programs.

How the Company Makes Money

Apollo Hospitals generates revenue primarily through its hospital operations, which include inpatient and outpatient services. The company charges fees for various medical services, surgeries, and treatments provided in its hospitals. Additionally, Apollo earns significant income from its diagnostic services, including laboratory tests and imaging services. The retail pharmacy segment contributes to revenue by selling prescription and over-the-counter medications, health products, and wellness services. Strategic partnerships with insurance companies and health plans also enhance revenue through reimbursements for services rendered. Furthermore, Apollo has ventured into digital health initiatives, which provide an additional revenue stream through telemedicine and online consultations.

Apollo Hospitals Enterprise Limited Financial Statement Overview

Summary

Apollo Hospitals demonstrates strong financial performance with robust revenue growth, improved profitability, and efficient cash flow management. The balance sheet is stable, though debt management remains crucial.

Income Statement

Apollo Hospitals shows strong revenue growth with a significant increase in total revenue over the past year. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, demonstrating increased profitability. Both EBIT and EBITDA margins are robust, reflecting effective operations and earnings before interest, taxes, depreciation, and amortization.

Balance Sheet

The company's balance sheet reflects a stable financial position with a reasonable debt-to-equity ratio, suggesting manageable leverage. The equity ratio indicates a strong capital structure. The return on equity shows good profitability from shareholders' investments, though there is room for improvement.

Cash Flow

Apollo Hospitals maintains strong operating cash flow, which covers net income well, indicating efficient cash conversion. The free cash flow growth rate is commendable, although the capital expenditures have increased, impacting free cash flow. The company shows effective cash management to support operations and future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	225.50B	217.94B	190.59B	166.13B	146.63B	105.60B
Gross Profit	76.27B	73.50B	63.98B	56.68B	51.31B	31.40B
EBITDA	29.83B	27.98B	22.11B	19.11B	20.45B	9.75B
Net Income	15.90B	14.46B	8.99B	8.19B	10.56B	1.50B
Balance Sheet
Total Assets	0.00	206.57B	167.53B	144.28B	131.92B	114.17B
Cash, Cash Equivalents and Short-Term Investments	20.10B	27.93B	11.89B	7.26B	10.48B	14.23B
Total Debt	0.00	78.64B	53.33B	43.32B	40.68B	41.60B
Total Liabilities	-86.53B	120.05B	94.33B	78.96B	73.15B	66.14B
Stockholders Equity	86.53B	82.12B	69.35B	61.97B	56.23B	46.02B
Cash Flow
Free Cash Flow	0.00	2.16B	7.83B	2.49B	9.71B	9.78B
Operating Cash Flow	0.00	19.29B	19.20B	13.77B	16.28B	12.73B
Investing Cash Flow	0.00	-34.77B	-15.37B	-8.71B	-8.47B	-8.72B
Financing Cash Flow	0.00	16.21B	-3.11B	-6.33B	-7.93B	-3.40B

Apollo Hospitals Enterprise Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7883.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Positive. The current price of 7883.35 is above the 20-day moving average (MA) of 7755.02, above the 50-day MA of 7767.44, and above the 200-day MA of 7106.91, indicating a bullish trend. The MACD of 60.96 indicates Negative momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 31.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:APOLLOHOSP.

Apollo Hospitals Enterprise Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDANTA	―	₹372.21B	68.98	―	0.04%	15.42%	10.66%
NH	―	₹362.74B	45.97	―	0.25%	12.09%	-2.79%
FORTIS	―	₹824.98B	94.33	―	0.09%	14.04%	32.99%
APOLLOHOSP	―	₹1.14T	72.27	―	0.24%	14.31%	51.71%
MAXHEALTH	―	₹1.15T	99.96	―	0.13%	32.65%	8.86%
METROPOLIS	―	₹98.98B	64.71	―	―	12.86%	10.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%